Conditions: Nonalcoholic Steatohepatitis Non-alcoholic Fatty Liver Disease
Keywords: NAFLD NASH
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 38
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the safety and efficacy of IDN-6556 compared to placebo in patients with diagnosed fat deposits in their liver (not caused by alcohol) and with abnormal liver tests

Detailed description:
This is a double-blind, randomized study to evaluate the effects of IDN-6556 on serum transaminases and pharmacodynamics of IDN-6556 in subjects with non-alcoholic fatty liver disease with elevated alanine aminotransferase.

Arms:
arm 1: IDN-6556 capsules, 25 mg BID arm 2: Placebo BID

Interventions: intervention 1: IDN-6556 intervention 2: Placebo
Intervention descriptions: intervention 1: 25 mg BID for 28 days intervention 2: Placebo BID for 28 Days

Protocol document: